A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase III Study of Ficlatuzumab in Combination with Cetuximab in Participants with Recurrent or Metastatic R/M HPV-Negative Head and Neck Squamous Cell Carcinoma FIERCE-HN

Brief Summary

Type:
Head and Neck Cancers

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT06064877

Study #:
STUDY00150901

Start Date:
Mar 26, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06064877

View Complete Trial Details & Eligibility at ClinicalTrials.gov